Method for treating liver cancer using orally administered dioxolane nucleotides in combination with anti-PD1 or anti-PDL1 monoclonal antibody

摘要

The following formula (I) in the treatment of liver cancer in a mammal, characterized in that the mammal is simultaneously or sequentially treated with a monoclonal antibody that blocks the binding of PD-L1 and/or PD-L2 to PD-1 of, or a pharmaceutically acceptable salt thereof.